IFNB1 and myeloid sarcoma: A retrospective analysis of a large pediatric MS cohort found that among those receiving GA (n = 53) and IFN-β (n = 200), 20% and 30%, respectively, were switched to a different therapy after a mean of 1.3 years due to refractory disease [32].